Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY: NVO )

86.26 +0.62 (+0.72%)
Official Closing Price Updated: 7:00 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,774,744
Open 87.22
Bid (Size) 85.80 (1)
Ask (Size) 86.48 (2)
Prev. Close 85.64
Today's Range 85.84 - 87.28
52wk Range 81.50 - 148.15
Shares Outstanding N/A
Dividend Yield 1.19%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025
These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal portfolio anchor stocks for a long-term investor. 
Via The Motley Fool
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political

Performance

YTD
-1.44%
-1.44%
1 Month
-19.35%
-19.35%
3 Month
-27.98%
-27.98%
6 Month
-38.99%
-38.99%
1 Year
-18.89%
-18.89%

More News

Read More
Best Healthcare Stock to Buy: Eli Lilly vs. Novo Nordisk
Via The Motley Fool
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals
Via Benzinga
Is Novo Nordisk an Undervalued Stock to Buy Now?
Via The Motley Fool
What's Going on With Novo Nordisk Stock?
Via The Motley Fool
Better Buy: Novo Nordisk vs. AstraZeneca
Via The Motley Fool
This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly
Via The Motley Fool
Jim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower
Via Benzinga
Novo Nordisk's Sponsorship Deals With UK Pharmacies Linked To Weight-Loss Drugs Raise Ethical Concerns
Via Benzinga
Investors Look Back at 2024
Via The Motley Fool
Topics Stocks
Exposures US Equities
Here's How Much $1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today
Via Benzinga
Novo Nordisk's Options: A Look at What the Big Money is Thinking
Via Benzinga
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
Via Benzinga
President-Elect Trump Poses Challenge To U.S. Tech Sales
Via Investor's Business Daily
Topics Government World Trade
Exposures Political Tariff
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
Via Benzinga
Exposures Product Safety
3 Trends To Watch
Via Talk Markets
Topics Stocks / Equities
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
Via Benzinga
4 Top Stocks to Buy in January
Via The Motley Fool
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
Via Benzinga
Should You Buy the Dip in Novo Nordisk Stock Right Now?
Via The Motley Fool
Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Via MarketBeat
Topics Economy Energy
Exposures Economy Fossil Fuels Interest Rates
While growth is established for NYSE:NVO, the stock's valuation remains reasonable.
Via Chartmill
Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?
Via The Motley Fool
3 Stocks That Could Be Monster Winners in 2025
Via The Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.